Aidi Injection, Compound Kushen Injection, or Kanglaite Injection: Which Is the Best Partner with Systemic Chemotherapy for Patients with HCC? A Network Meta-Analysis

Table 1

Details of the characteristics of the studies.

Study ID (author, year)		N (E/C)	M/F	Average age (E/C)	Stage	KPS (E/C)	Treatment (E/C)	Duration	Outcomes^c
Study 1 (Huang et al., 2002) [10]		30/28	43/15	57.6/56.2	II–IV	NR	Aidi Inj+5Fu/5Fu	28d^∗4	1, 2, 3, 4, 5
Study 2 (Hou et al., 2017) [11]		43/43	45/41	55.7/58.2	II–IV	69.27/71.34	Aidi Inj+5Fu/5Fu	30d^∗1	1, 2, 3, 4
Study 3 (Hou, 2018) [12]		47/47	57/37	54.57/56.24	II–IV	62.23/62.41	Aidi Inj+CAFI/CAFI	28d^∗2	1, 2
Study 4 (Hongwen et al., 2012) [13]		36/36	48/24	52/54	NR	≥60/≥60	Aidi Inj+FOLFOX4/FOLFOX4	28d^∗4	1, 2, 3, 4, 6
Study 5 (Zhang, 2018) [14]		35/35	33/37	54.93/55.21	NR	62.19/62.34	Aidi Inj+XELOX/XELOX	14d^∗4	1, 2
Study 6 (Zhang, 2018) [15]		35/34	39/30	58.60/58.20	III–IV	NR	Aidi Inj+XELOX/XELOX	21d^∗4	1, 2, 4
Study 7 (Zhang and Wang, 2007) [16]		24/18	30/12	Range: 32–75^a	III–IV	≥60/≥60	Aidi Inj+DDP+5Fu/DDP+5Fu	28d^∗2	1, 2, 3, 4
Study 8 (Shi and Wang, 2011) [17]		35/35	36/34	51.3/52.9	III–IV	NR	Aidi Inj+DDP+EPI/DDP+EPI	21d^∗2	1, 2, 3, 5
Study 9 (Liu et al., 2013) [18]		30/30	33/27	55/56	II–III	NR	Kushen Inj+MAF/MAF	21d^∗3	1, 2, 4
Study 10 (Chen and Xun, 2006) [19]		16/14	19/11	63.4/65.3	II–III	≥50/≥50	Kushen Inj+FAP/FAP	28d^∗2	1, 2, 3, 4
Study 11 (Jin, 2016) [20]		36/36	42/30	54.3^a	II–IV	NR	Kushen Inj+GEMOX/GEMOX	21d^∗2	1, 2, 4
Study 12 (He, 2018) [21]		43/43	49/37	60.4/59.2	II–IV	64.76/63.98	Kushen Inj+FOLFOX6/FOLFOX6	21d^∗6	1, 2, 4
Study 13 (Li et al., 2018) [22]		40/40	51/29	53.8/51.3	III–IV	NR	Kushen Inj+MAF/MAF	21d^∗3	1, 2
Study 14 (Shi, 2011) [23]		30/30	35/25	52.8/53.4	IIIb–IV	≥60/≥60	Kushen Inj+GP/GP	30d^∗2	1, 2, 4
Study 15 (Wu et al., 2002) [24]		30/30	53/7	42/43	II–III	NR	Kushen Inj+FUDR/FUDR	20d^∗1	1, 2, 3, 4
Study 16 (Guan et al., 2006) [25]		20/18	NR	Range: 26–65^a	III	≥50/≥50	Kushen Inj+GEMOX^b/GEMOX	15d^∗4	1, 2, 3, 5
Study 17 (Yao, 2015) [26]		30/30	35/25	55/56	NR	NR	Kushen Inj+GEMOX/GEMOX	21d^∗2	1, 2
Study 18 (Xu et al., 2010) [27]		38/37	58/17	48.5^a	II–III	NR	Kanglaite Inj+CAP/CAP	21d^∗2	1, 2, 3, 4, 6, 7
Study 19 (Ma et al., 2017) [28]		43/43	38/48	54.8/53.7	NR	56.24/58.49	Kanglaite Inj+FOLFOX6/FOLFOX6	21d^∗2	1, 2, 8
Study 20 (Li et al., 2014) [29]	75/75	79/71	53.2/52.1	I–IV	NR	Kanglaite Inj+ADM/ADM	30d^∗2	1, 2, 3, 4, 5, 8

N: number; E: experimental group; C: control group; M: male; F: female; NR: not reported; Inj: injection. ^aMerged data of two groups; ^bthere were 3 kinds of chemotherapy protocol in this article: GEMOX, GEM+5–Fu+THP, and HCPT+FT207+THP; ^c1=objective response rate; 2=clinical benefit rate; 3=KPS; 4=adverse reactions; 5=overall survival; 6=time to progress; 7=median survival time; 8=immune function.